Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**IMAGION BIOSYSTEMS LIMITED**
ABN	**42 616 305 027**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark **VAN ASTEN**
Date of last notice	26 June 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 August 2020
No. of securities held prior to change	i) 470,000 Shares ii) 75,000 Listed Options (exercisable at $0.05, expiring on 26 November 2021) iii) 120,000 Listed Options (exercisable at $0.03, expiring on 28 April 2023)
Class	i) Fully Paid Ordinary Shares (**Shares**) ii) Listed Options (exercisable at $0.05, expiring on 26 November 2021) iii) Listed Options (exercisable at $0.03, expiring on 28 April 2023)

Number acquired	i) Nil Shares ii) Nil Listed Options (exercisable at $0.05 expiring on 26 November 2021) iii) Nil Listed Options (exercisable at $0.03 expiring on 28th April 2023) iv) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) v) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	i) N/A per Share ii) N/A Listed options (exercisable at $0.05 expiring on 26 November 2021) iii) N/A Listed options (exercisable at $0.03 expiring on 28th April 2023) iv) Nil Consideration for Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) v) Nil Consideration for Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027)
No. of securities held after change	i) 470,000 Shares ii) 75,000 Listed options (exercisable at $0.05, expiring on 26 November 2021) iii) 120,000 Listed options (exercisable at $0.03, expiring on 28 April 2023) i) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) iv) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted Performance Options were issued as part of the Company's EIP as outlined in the Notice of Annual General Meeting to Shareholders on the 19th July 2020 and approved by the shareholders at the Company's 2020 AGM.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.